Pieris and Syngenta Collaborate to Develop Anticalin

Pieris Proteolab AG, a biopharmaceutical and protein engineering company has signed an agreement with the biopharmaceutical unit of Syngenta AG of Basel, Switzerland, to develop an Anticalin based drug for an indication with high unmet medical need. Anticalins are engineered receptor proteins with antibody-like functions, which are derived from natural human lipocalin scaffolds, a class of proteins designed by nature to have many different protein and hapten binding functions.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-13-2005/0003387748&EDATE=)